Company Research Report: Espansione Group

Company Overview

• Name: Espansione Group

• Mission: Helping people through science. The company aims to establish new paradigms in ophthalmology and beyond, providing partners and their patients with certified medical technologies.

• Founded: 1981

• Founder: No information is available

• Key People:

• Marco Ferrari, Country Head for Italy

• Massimo Tedoldi, General Manager at Visionix Italy

• Headquarters: Blocco 27, Via Degli Orefici 152, Centergross, Funo (BO), 40050, Italy

• Number of Employees: No information is available

• Revenue: No information is available

• What the Company is Known For: Espansione Group is recognized for its high standard in the industry with innovative light-based medical technologies, specifically in ophthalmology and dermatology.

Products

Ophthalmology Solutions

1. eye-light®

• Description: A comprehensive eye care solution leveraging LM® LLLT and OPE® IPL technologies.

• Key Features:

• Manages anterior and posterior segment conditions.

• Utilizes light-based therapy for effective treatment.

2. meibomask®

• Description: A professional solution utilizing LM® LLLT technology.

• Key Features:

• Intended for anterior segment conditions like DED/MGD.

• Provides effective light modulation therapy.

3. my-mask®

• Description: A portable and lightweight device for anterior segment conditions.

• Key Features:

• Uses LM® LLLT technology.

• Offers effective management through photobiomodulation.

4. me-check®

• Description: A medical device for quick and easy screening.

• Key Features:

• Modular and actionable.

• Screens for ocular surface conditions.

Dermatology & Trichology Solutions

1. young again®

• Description: Utilizes Light Modulation® LLLT for skin and hair conditions.

• Key Features:

• Non-invasive treatment.

• Addresses skin and hair concerns effectively.

Recent Developments

• New Products Launched:

• MeiboMetrics: An AI-powered algorithm for meibomian gland segmentation and quantitative measurement, developed in partnership with Reykjavik University. Set to launch in 2025 on me-check® Pro and other platforms.

• New Features Added to Existing Products:

• Enhanced light therapy features in eye-light® for managing dry AMD and dAMD confirmation through the LightWave I Clinical Trial.

• Partnerships and Collaborations:

• Visionix Italy: A strategic partnership aimed at enhancing eye care solutions in Italy, effective from April 1, 2024.

• Reykjavik University: Partnered to develop MeiboMetrics, advancing in AI-powered eye care technology.

• Additional Partnerships: With Rodenstock Norge AS and Topcon Healthcare in various regions to drive innovation in eye care.

• Clinical Developments:

• Completion and publication of findings from the LightWave I clinical trial, demonstrating the efficacy and safety of LM® LLLT in treating dry Age-related Macular Degeneration (dAMD).

• Announcement of innovative research like the DRUSEN Study which highlights new developments and validates therapeutic interventions for eye conditions.

This extensive market report provides insights into the key areas of Espansione Group's operations, revealing their significant presence in the medtech industry with a focus on innovative light-based therapies in the realms of ophthalmology and dermatology.